Defining and treating moderate plaque psoriasis: a dermatologist survey

Knuckles, Melissa; Levi, Eugenia; Soung, Jennifer

doi:10.1080/09546634.2018.1443200

Cited by 23 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings from the online survey were previously reported (11). The current analysis describes the chart findings from the subset of patients treated with apremilast who had !1 follow-up visit during the 6-month follow-up period.…”

Section: Dermatologist Surveymentioning

confidence: 78%

“…The survey was previously described in detail (11). Briefly, the survey was conducted among US dermatologists treating patients with psoriasis during October 2015.…”

Section: Dermatologist Surveymentioning

confidence: 99%

“…Among the 173 dermatologists who were contacted, 23 did not fit the inclusion criteria for participation. The remaining 150 dermatologists responded to the survey (11); 83 responded at both time points and provided 6-month follow-up information for patients with moderate psoriasis who were receiving treatment with apremilast at the time of the initial survey. The dermatologists who participated in the chart review (n ¼ 83) had an average of 14 years in practice.…”

Section: Respondent Dermatologistsmentioning

confidence: 99%

“…The objectives of the present study were to describe real-world clinical characteristics and 6month treatment outcomes among patients with moderate plaque psoriasis treated with apremilast. The current analysis describes the chart findings of dermatologists identified in the previously published dermatologic survey (11); data are from the subset of patients treated with apremilast who had !1 follow-up visit during the 6-month follow-up period.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

Knuckles

Levi²,

Soung³

2018

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%). However, findings from realworld clinical practice are limited. Materials and methods: An online survey and chart review was conducted among US dermatologists during October 2015 to identify clinical characteristics and 6-month treatment outcomes among patients with moderate psoriasis treated with apremilast. Results: A total of 83 dermatologists provided patient chart information at the initial and 6-month follow-up time points for 70 patients with moderate plaque psoriasis initially receiving apremilast, of whom 65 were receiving it as their primary therapy (mean age: 47.3 years; 45% were men). Among apremilasttreated patients, 91% (64 of 70) remained on apremilast and 54% were rated as having improved to mild psoriasis at follow-up; mean BSA decreased from 9.9% at initial chart review to 4.9%. There were 8 of 66 (12%) patients who experienced !1 side effect, including diarrhea (7.6%), nausea (4.5%), headache (1.5%), and abdominal pain (4.5%). Most dermatologists (68%) stated that apremilast exceeded or met their expectations. Conclusions: Most patients with moderate psoriasis receiving apremilast had improved at 6-month follow-up. Safety and tolerability were consistent with the safety profile of apremilast.

show abstract

Section: Dermatologist Surveymentioning

confidence: 78%

“…The survey was previously described in detail (11). Briefly, the survey was conducted among US dermatologists treating patients with psoriasis during October 2015.…”

Section: Dermatologist Surveymentioning

confidence: 99%

Section: Respondent Dermatologistsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast

Knuckles

Levi²,

Soung³

2018

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Guidelines for psoriasis tend to group ill-defined moderate psoriasis patients with the more severe population, and this group can receive any form of therapy as first line, including phototherapy, biologics, and systemics (26). However, patients may have contra-indications to systemic agents or may be reluctant to initiate systemic therapy.…”

Section: Discussionmentioning

confidence: 99%